Here we report on a new thienylpyrazoloquinoline compound, 5 (S-135), which is a potent and orally active inverse agonist with high affinity to BZ receptors but produces no convulsions by itself. Furthermore, its regioisomer 7, also having a high affinity to BZ receptors, is classified as an agonist.